Atossa Therapeutics (ATOS) Current Deferred Revenue (2013 - 2014)
Atossa Therapeutics (ATOS) posted quarterly Current Deferred Revenue of $8549.0 for Q3 2014, down 85.93% year-over-year from $60753.0 in Q3 2013, and down 60.0% quarter-over-quarter from $21372.0 in Q2 2014.
Atossa Therapeutics (ATOS) Current Deferred Revenue (2013 - 2014) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Current Deferred Revenue for 2 consecutive years, with $8549.0 the latest figure, recorded in Q3 2014.
- In Q3 2014, Current Deferred Revenue fell 85.93% year-over-year to $8549.0; the TTM figure through Sep 2014 stood at $8549.0 (down 85.93% YoY), while the FY2013 annual figure was $48157.0, changed N/A from the prior year.
- Current Deferred Revenue fell to $8549.0 in Q3 2014 per ATOS's latest filing, from $21372.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $72537.0 in Q2 2013 and bottomed at $8549.0 in Q3 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | 8,549.00 |
| Jun 30, 2014 | 21,372.00 |
| Mar 31, 2014 | 35,023.00 |
| Dec 31, 2013 | 48,157.00 |
| Sep 30, 2013 | 60,753.00 |
| Jun 30, 2013 | 72,537.00 |